{rfName}
Co

Indexed in

License and use

Icono OpenAccess

Citations

19

Altmetrics

Analysis of institutional authors

Herranz PAuthor

Share

February 11, 2022
Publications
>
Article
Sí

Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment

Publicated to:Dermatology and Therapy. 12 (1): 195-202 - 2022-01-01 12(1), DOI: 10.1007/s13555-021-00643-4

Authors: Armstrong, April; Blauvelt, Andrew; Simpson, Eric L; Smith, Catherine H; Herranz, Pedro; Kataoka, Yoko; Seo, Seong Jun; Ferrucci, Silvia M; Chao, Jingdong; Chen, Zhen; Rossi, Ana B; Shumel, Brad; Tomondy, Paul

Affiliations

Chung Ang Univ Hosp, Seoul, South Korea - Author
Fdn Irccs Ca Granda Osped Maggiore Policlin, Milan, Italy - Author
La Paz Univ Hosp, Madrid, Spain - Author
Oregon Hlth & Sci Univ, Portland, OR 97201 USA - Author
Oregon Med Res Ctr, Portland, OR USA - Author
Osaka Habikino Med Ctr, Dept Dermatol, Osaka, Japan - Author
Pvaluecomm, Cedar Knolls, NJ USA - Author
Regeneron Pharmaceut Inc, Tarrytown, NY USA - Author
Sanofi Genzyme, Cambridge, MA USA - Author
St Johns Inst Dermatol, London, England - Author
Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA - Author
See more

Abstract

Introduction: Previous drug survival studies of dupilumab in atopic dermatitis (AD) show that many patients continue treatment through 1 year, suggesting that patients experience clinically relevant benefits with long-term treatment. Methods: This post hoc analysis included data through week 100 from 391 adult patients from the dupilumab open-label extension (OLE) study who had not achieved the endpoints of at least 75% improvement from baseline in the Eczema Area and Severity Index (EASI-75) or an Investigator’s Global Assessment (IGA) score of 0 or 1 with short-term (16 weeks, 300 mg qw or q2w) dupilumab treatment in the parent SOLO 1 or 2 studies. All patients received dupilumab 300 mg qw in the OLE study, irrespective of whether they received qw or 2qw dosing in the parent study. Results: Among those who had not achieved EASI-75 or IGA 0/1 during the 16-week parent study, the proportion of patients achieving EASI-75 by week 100 was 91%. The proportion achieving IGA 0 or 1 at week 100 was 45% for patients initially on q2w week dosing and 49% for those on initial qw dosing. Conclusion: Long-term dupilumab treatment may be associated with improvement in AD in patients with suboptimal responses during the initial 16 weeks of treatment. Clinical Trial Registration: LIBERTY AD SOLO 1: ClinicalTrials.gov identifier NCT02277743; EudraCT 2014-001198-15. LIBERTY AD SOLO 2: ClinicalTrials.gov identifier NCT02277769; EudraCT 2014-002619-40. LIBERTY AD OLE: ClinicalTrials.gov Identifier NCT01949311; EudraCT 2013-001449-15.

Keywords

atopic dermatitisdupilumabAtopic dermatitisDupilumabEfficacy

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Dermatology and Therapy due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Dermatology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 3.29. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 3 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 4.41 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-18, the following number of citations:

  • WoS: 8
  • Scopus: 9

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-18:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 21.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 22 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 0.5.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Italy; Japan; Republic of Korea; United Kingdom; United States of America.